Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Gut Liver. 2022 Jan 15;16(1):81-91. doi: 10.5009/gnl210064.
BACKGROUND/AIMS: This study aimed to investigate the perceptions and behaviors of patients with inflammatory bowel disease (IBD) during the early coronavirus disease 2019 (COVID-19) pandemic in the major epidemic area in Korea.
Between April and May 2020, a cross-sectional survey was performed at two tertiary hospitals in Daegu, South Korea, on patients' experiences, coping strategies and perceptions.
Most of the 544 patients participating in the survey strictly adhered to personal protection guidance against COVID-19. In the early COVID-19 crisis, many patients canceled or postponed hospital visits (57.5%) and rescheduled biologics administrations (26.4%). Although 13.6% utilized telemedicine, the frequency of individuals leaving their homes remained unchanged. Although 50.4% were concerned about their susceptibility to COVID-19, 72.2% adhered to their treatment for IBD. In patients taking biologics or Janus kinase inhibitors, 86.8% disagreed that they should discontinue their medication as a preventative measure against COVID-19, but 21.9% actually discontinued their medications. Of those with discordance between the perception of IBD drug adherence and active behaviors, 5.4% of all and 39.4% of biologics or Janus kinase inhibitors withheld drugs specifically due to fear of COVID-19. Only 7% of all patients discussed drug safety with their physicians. The level of concern for COVID-19 depended on the type of drug used.
Patients with IBD showed concerns about the increased risk of COVID-19 due to IBD or their medications, and a considerable number of patients withheld their medications without consulting medical staff. Enhanced active communications with patients with IBD and appropriate health-related education should be provided.
背景/目的：本研究旨在调查韩国主要疫区的炎症性肠病（IBD）患者在 2019 年冠状病毒病（COVID-19）大流行早期的认知和行为。
2020 年 4 月至 5 月，在韩国大邱的两家三级医院进行了一项横断面调查，调查了患者的经历、应对策略和认知。
参与调查的 544 名患者中，大多数人严格遵守针对 COVID-19 的个人防护指导。在 COVID-19 危机早期，许多患者取消或推迟了医院就诊（57.5%）并重新安排了生物制剂给药（26.4%）。尽管 13.6%的人使用了远程医疗，但个人离家的频率保持不变。尽管 50.4%的人担心自己易感染 COVID-19，但 72.2%的人仍坚持治疗 IBD。在服用生物制剂或 Janus 激酶抑制剂的患者中，86.8%的人不同意将药物停用作为预防 COVID-19 的措施，但实际上有 21.9%的人停用了药物。在对 IBD 药物依从性的认知和积极行为之间存在差异的患者中，有 5.4%的患者和 39.4%的生物制剂或 Janus 激酶抑制剂患者因担心 COVID-19 而特意停止用药。只有 7%的患者与医生讨论过药物安全性。对 COVID-19 的关注程度取决于所用药物的类型。
IBD 患者对 IBD 或其药物增加 COVID-19 风险表示担忧，相当一部分患者在未咨询医务人员的情况下停药。应与 IBD 患者进行更积极的沟通，并提供适当的与健康相关的教育。
